MENLO PARK, Calif., June 10, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark ...

Please provide your email address to receive an email when new articles are posted on . A genetic biomarker test was able to predict patients’ semaglutide treatment response after bariatric surgery.

The studies, led by Mayo Clinic researcher and Phenomix co-founder Andres Acosta, MD, PhD, further validate the MyPhenome test's ability to predict patient response to GLP-1 therapies such as ...

As effective as the new weight loss drugs like Wegovy and Zepbound are, they don’t work for everyone. Mayo Clinic obesity expert Dr. Andres Acosta and his team studied thousands of obesity patients to ...